Biolife Solutions, Inc. · NASDAQ:BLFS
Biolife Solutions — Investor Presentation (November 2025)
28 slides from Biolife Solutions's investor presentation, Nov 17, 2025
Slide 1: Investor Presentation November 2025
Investor Presentation November 2025
Slide 2: Safe Harbor Statement
2 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® Safe Harbor Statement Certain statements contained in this presentation are not historical facts and may be forward- looking statements within the meaning of the Private Securities Litigation
Slide 3: Our Mission
3 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 Our Mission Our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that enable our customers to advance and de-risk the development and delivery of cell-based therapies © Copyright 20
Slide 4: BioLife at a Glance
4 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® BioLife at a Glance Leading provider of biopreservation and processing tools for cell-based therapies Note: 2025 estimated figures pro forma for the divestiture of evo. (1) Reflects specificat
Slide 5: Years of Innovation in Cell-Based Applications
5 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® 28 Years of Innovation in Cell-Based Applications 1987 - 2002 2003 - 2013 2014 - 2018 2023 - 20252019 - 2022 Scientific Foundation Biopreservation Focus Becoming Gold Standard Adjacency Expans
Slide 6: Executed Successful Portfolio Refocusing
6 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® Executed Successful Portfolio Refocusing Note: 2025 estimated figures pro forma for the divestiture of evo. (1) Excludes prior-year COVID-related revenue. (2) Reflects cash & cash equivalents
Slide 7: BioLife Supports Diverse Cell-Based Applications
7 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 Genetic Modification Therapy Delivery Sample Collection Expansion (of gene- modified cells) © Copyright 2025 BioLife Solutions® BioLife Supports Diverse Cell-Based Applications BioLife provides solutions for therapies involving
Slide 8: BioLife Solutions Product Platforms
8 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 13% BioLife Solutions Product Platforms Cell Processing Tools BioLife’s cell processing tools support critical steps in the preparation, transfer, and recovery of cell-based therapies by enhancing efficiency and reproducibility
Slide 9: BioLife Solutions Key Products
9 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 Pathogen-reduced and xeno-free supplements that support faster cell growth, higher yield, and improved functionality during cell expansion BioLife Differentiation Innovating vs. Traditional Options © Copyright 2025 BioLife Solut
Slide 10: BioLife Products Used Throughout a Typical Cell-Based Therapy Workflow
10 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® BioLife Products Used Throughout a Typical Cell- Based Therapy Workflow Upstream Processing Downstream Processing Cells are collected from the patient or donor and sent to manufacturing Targe
Slide 11: Trusted by Leaders in Cell-Based Therapies
11 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 Active US, Commercially Sponsored Cell-Based Therapy Trials and US Approved Cell-Based Therapies © Copyright 2025 BioLife Solutions® A significant number of active clinical trials and commercial cell-based therapies are support
Slide 12: Embedded Across Cell-Based Applications
12 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® Embedded Across Cell-Based Applications Therapy Type Cell Source Therapeutic Area Breakdown of active US, commercially-sponsored cell-based therapy clinical trials in which biopreservation me
Slide 13: CryoStor: Industry-Leading Cryopreservation Solution with High Switching Costs
13 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® CryoStor®: Industry-Leading Cryopreservation Solution in a Market with High Switching Costs CryoStor® Differentiation Obstacles to Switch by Phase Performance (Cell Viability) Regulatory Docu
Slide 14: Diversity of Products and Multi-Product Specification
14 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® Diversity of Products and Multi-Product Specification Greater specification of non-CryoStor® products and increasing multi-product specification in global early-stage trials position BioLife
Slide 15: Cell-Based Therapy Market Positioned To Grow 20%+
15 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 +12% ‘25-’30 CAGR 23K 30K 50K33K Global Number of Cell-Based Therapy Patients (Clinical & Commercial) 34K 42K 59K 68K 74K 81K 89K $1.1 $1.7 $2.7 $3.8 $4.8 $6.7 $9.2 $12.1 $14.6 $17.0 $19.0 '20 '21 '22 '23 ' 4 '25F '26F '27F '28
Slide 16: Large ~$4B Total Addressable Market for BioLife
16 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® Large ~$4B Total Addressable Market for BioLife Current Market Opportunity Breakdown (2025) Addressable by BioLife Today Future Expansion Potential Source: Advancy. Total Biopreservation and
Slide 17: Customer Case Study: Trusted Partner Across the Workflow
17 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 2021 2025F Customer Annual Revenue © Copyright 2025 BioLife Solutions® Customer Case Study: Trusted Partner for Solutions Across the Workflow Large biopharma with multiple commercial cell-based therapy programs Long-term relati
Slide 18: Organizational Overview
18 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® Organizational Overview Organizational Breakdown by Functional Area 24% 21% 19% 13% 13% 10% ~155 Employees Quality Manufacturing Finance Sales & Marketing R&D Corporate & Other Executive Team
Slide 19: Operational Footprint and Capabilities
19 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® Operational Footprint and Capabilities Overview of Key Facilities Media Capacity Expansion (Bothell, WA) • Additional GMP cleanroom with fill & formulation capability • $5.5M total investment
Slide 20: BioLife Solutions Financial Overview
20 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® BioLife Solutions Financial Overview Total Revenue ($M) Adjusted EBITDA ($M) $16 $18 $19 $21 $22 $23 $26 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Key Future Growth Drivers +32% YTD’25 % Grow
Slide 21: Investment Highlights
21 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® Investment Highlights (1) Based on EvaluatePharma. (2) Based on active US commercially sponsored cell-based therapy trials; reflects specification of biopreservation media products (CryoStor®
Slide 22: Thank you
~. Biolife WS Solutions Thank you Pregenving the prewedge
Slide 23: GAAP to Non-GAAP Financial Information
23 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® GAAP to Non-GAAP Financial Information
Slide 24: GAAP Gross Profit to Non-GAAP Gross Profit
24 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® GAAP Gross Profit to Non-GAAP Gross Profit Estimated figures pro forma for the divestiture of evo (In thousands) Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY2024 Total revenues $ 16,485 $ 18,042 $ 19,4
Slide 25: GAAP Gross Profit to Non-GAAP Gross Profit
25 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® GAAP Gross Profit to Non-GAAP Gross Profit Estimated figures pro forma for the divestiture of evo (In thousands) Q1 2025 Q2 2025 Q3 2025 YTD 2025 Total revenues $ 22,053 $ 23,438 $ 25,958 $ 7
Slide 26: GAAP to Non-GAAP Adjusted EBITDA
26 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® GAAP to Non-GAAP Adjusted EBITDA Estimated figures pro forma for the divestiture of evo (In thousands) Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY2024 Income (loss) from continuing operations $ (2,715
Slide 27: GAAP to Non-GAAP Adjusted EBITDA
27 | Industry-Leading Solutions for Cell-Based Therapies | November 2025 © Copyright 2025 BioLife Solutions® GAAP to Non-GAAP Adjusted EBITDA Estimated figures pro forma for the divestiture of evo (In thousands) Q1 2025 Q2 2025 Q3 2025 YTD 2025 Income (loss) from continuing operations $ 140 $ (15,45
Slide 28: BioLife Solutions Inc. contact details
BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310 Bothell, WA 98021 USA T +1.866.424.6543 or 425.402.1400 F +1.425.402.1433 E info@biolifesolutions.com biolifesolutions.com NASDAQ: BLFS For additional questions or comments Roderick De Greef | Chief Executive Officer rdegreef@BioLifeSolution
BioLife Solutions — Investor Presentation (November 2025) on 6ix